RESOURCES

Two hot and emerging areas in drug discovery include the E3 ligases in targeted protein degradation (TPD) and SRC homology 2 (SH2) domain-containing proteins.

GPCR-based peptide therapeutics, particularly those targeting GLP-1, GIP, and glucagon receptors, offer tremendous potential in combating the global obesity crisis.

The FDA ICH S1B (R1) guidance have introduced a Weight of Evidence (WoE) approach for evaluating human carcinogenic risk in drug development.

A leading cause of drug attrition, warnings and market withdrawals is drug mediated hepatotoxicity resulting from biotransformation.

Developing a cell-based model using iPSC-derived microglia introduces an alternative method to animal cell models and immortalized cell lines that is more physiologically relevant to a patient-specific context.

Drug-induced Liver Injury (DILI) remains a major obstacle in drug development. Despite the use of various models, DILI continues to lead to drug attrition, post-market withdrawals, and safety warnings. Recent advancements in 3D culture of PHHs as spheroids have shown promise in overcoming these limitations.

Secondary pharmacology screening data are typically included in investigational new drug applications to define clinical candidates’ selectivity profiles and assess off-target activity risks.

De-risk your investments with our expertise.

Access Comprehensive Oncology Solutions for All Therapeutics Modalities

A novel affinity-based screening approach using the Spectral Shift (SpS) technology was developed at Eurofins Discovery for hit finding programs. In the context of kinase drug discovery, conventional approaches focus on activity-based assays targeting the ATP site. Using this direct biophysical measurement, we can identify allosteric binders that would be missed during conventional HTS.

Leverage our fully automated synthesis platform to speed-up your drug discovery programs.

Rapidly Identify Candidates with Desirable Pharmacokinetic Profiles